Compare Boston Scientific Corporation (BSX) vs Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? Boston Scientific Corporation trades at $42.27 (market cap $66.37B), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $30.37. The key difference: Roundhill Innov-100 0DTE Covered Call Strat ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | QDTE | |
|---|---|---|
Market Cap | $66.37B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $108.14 | $36.60 |
52-Week Low | $42.63 | $26.85 |
Enterprise Value | $75.94B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
QDTE (Roundhill Innovation-100 0DTE Covered Call Strategy ETF) trades at $29.98, down 1.69% with a bearish technical signal. The ETF employs a weekly covered call strategy on Nasdaq-100 components, generating high distribution yields through 0DTE options. Recent dividend payments show consistent weekly distributions, though the yield has compressed as volatility declined. Technical indicators show mixed signals with neutral oscillators but bearish moving averages.
The ETF faces headwinds from declining volatility reducing option premiums, potentially impacting future distribution rates. While the weekly income stream appeals to income investors, the strategy's sustainability depends on market conditions. Current technical weakness suggests near-term pressure, though the high-yield strategy remains attractive for income-focused portfolios in stable markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Roundhill Innov-100 0DTE Covered Call Strat ETF
QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →
